Drug Profile
Encoberminogene rezmadenovec - Cornell University/Xylocor Therapeutics
Alternative Names: AdVEGF-A116A+ gene therapy - XyloCor Therapeutics; AdVEGF-All6A+; AdVEGFXC1; XC-001Latest Information Update: 11 Oct 2023
Price :
$50
*
At a glance
- Originator Cornell University
- Developer Cornell University; XyloCor Therapeutics
- Class Gene therapies; Ischaemic heart disorder therapies; Vascular disorder therapies
- Mechanism of Action Gene transference; Vascular endothelial growth factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Angina pectoris
- Preclinical Coronary artery disease
Most Recent Events
- 25 Aug 2023 Efficacy and adverse events data from the phase II EXACT trial in Angina pectoris was presented at the Annual Congress of the European Society of Cardiology (ESC-2023)
- 25 Aug 2023 Efficacy and adverse events data from a phase I/II EXACT trial in Angina pectoris (Intracardiac) released by Xylocor Therapeutics
- 18 Jul 2023 Efficacy data from phase-I/II EXACT trial in Angina pectoris released by XyloCor Therapeutics